Business Wire | TalkMarkets | Page 1
Global Leader In Press Release Distribution And Regulatory Disclosure
Contributor's Links: BusinessWire.com
Business Wire, a Berkshire Hathaway subsidiary, is a company that disseminates full-text news releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other ...more

Articles

Latest Posts
1 to 16 of 61 Posts
CERo Therapeutics, Inc. Announces Publication Of Preclinical Research Supporting The Use Of Its Clinical Candidate CER-1236 To Treat AML Patients
The paper details preclinical studies by CERo analyzing its lead clinical candidate CER-1236 in targeting Acute Myelogenous Leukemia (AML) tumor cells from human patients, and the candidate’s killing effects on these tumor cells.
Near Intelligence Announces Fourth Quarter And Full Year 2022 Financial Results
Near’s fourth quarter performance provided a solid finish to the year which was highlighted by 32% annual revenue growth and 120% net revenue retention.
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation Of RenovoGemTM As A Treatment Option For Locally Advanced Pancreatic Cancer
Renovo RX today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial.
Berkshire Hathaway Inc. First Quarter 2022 Earnings Release
Highlights to have handy as you monitor Berkshire's annual meeting this weekend.
James Hardie Industries Announces Third Quarter Fiscal Year 2022 Results
James Hardie Industries plc, the world’s #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, announced results for its third quarter fiscal year 2022, the three-month period ending Dec. 31, 2021.
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results And Provides Business Updates
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the second quarter of the fiscal year 2021.
Humana Reports Second Quarter 2021 Financial Results; Maintains Full Year 2021 Adjusted EPS Financial Guidance
Humana Inc. today reported consolidated pretax income and diluted earnings per common share for the quarter ended June 30, 2021.
Schlumberger Announces Second-Quarter 2021 Results
Schlumberger Limited today reported results for the second quarter 2021.
Virgin Galactic Successfully Completes First Fully Crewed Spaceflight
Fourth spaceflight tests private astronaut and research experience; first in-flight livestream brings spaceflight experience to audiences around the world.
Zoetis Announces First Quarter 2021 Results
Zoetis Inc. today reported its financial results for the first quarter of 2021 and increased its guidance for full-year 2021.
Emerson Reports Second Quarter 2021 Results, Raises 2021 Outlook
Emerson today reported results for the second fiscal quarter ended March 31, 2021.
Walgreens Boots Alliance Fiscal 2021 Second Quarter Results Exceed Expectations
Walgreens Boots Alliance, Inc. today announced financial results for the second quarter of fiscal 2021, which ended Feb. 28, 2021.
REX American Resources Reports Fiscal 2020 Fourth Quarter Results
REX American Resources Corporation today reported financial results for its fiscal 2020 fourth quarter (“Q4 ‘20”) ended January 31, 2021.
ADC Therapeutics Reports Fourth Quarter And Year-End 2020 Financial Results And Provides Business Updates
ADC Therapeutics SA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020, and provided business updates. 
Moderna Reports Fourth Quarter And Fiscal Year 2020 Financial Results And Provides Business Updates
Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2020, and highlighted pipeline progress.
Alnylam Launches “Alnylam P5x25” Strategy For Planned Transition To A Top Five Biotech In Market Capitalization Over Next Five Years
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced its new five-year strategy, “Alnylam P5x25,” which is focused on the company’s transition to a top-5 biotech (measured by market capitalization) in the next five years.
1 to 16 of 61 Posts